Buy Retatrutide in India

Q: What is Retatrutide?

{"type"=>"root", "children"=>[{"type"=>"paragraph", "children"=>[{"type"=>"text", "value"=>"Retatrutide, also known as LY3437943, is an investigational peptide designed for activity at the GIP, GLP-1 and glucagon receptors. It is studied as a triple receptor agonist in metabolic research."}]}]}

Q: Which receptors does Retatrutide target?

{"type"=>"root", "children"=>[{"type"=>"paragraph", "children"=>[{"type"=>"text", "value"=>"Published research describes Retatrutide as an agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor, glucagon-like peptide-1 (GLP-1) receptor and glucagon receptor."}]}]}

Q: What is Retatrutide studied for in laboratory research?

{"type"=>"root", "children"=>[{"type"=>"paragraph", "children"=>[{"type"=>"text", "value"=>"Retatrutide is studied in receptor-signaling, pharmacodynamic and metabolic-pathway research involving the GIP, GLP-1 and glucagon receptor systems. The product information on this page is presented for controlled in-vitro laboratory research context."}]}]}

Q: Is this Retatrutide product intended for laboratory research?

{"type"=>"root", "children"=>[{"type"=>"paragraph", "children"=>[{"type"=>"text", "value"=>"Yes. This product is presented for controlled in-vitro laboratory research only. Researchers should review the available batch documentation and follow applicable institutional and jurisdictional requirements."}]}]}

Q: What sources support the Retatrutide research summary?

{"type"=>"root", "children"=>[{"type"=>"paragraph", "children"=>[{"type"=>"text", "value"=>"The research summary is supported by peer-reviewed studies published in The Lancet and the New England Journal of Medicine. Full citations and reference links are listed in the Sources section of this product page."}]}]}

PRODUCT OVERVIEW

What is Retatrutide?

Retatrutide, also known as LY3437943, is an investigational peptide designed to activate the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. It is studied as a triple receptor agonist in receptor-signaling, pharmacodynamic, and metabolic-pathway research.

This product page presents Retatrutide as laboratory research material and connects the product to reusable research targets, glossary terms, FAQs, and scientific citations.

Purity>99% by HPLC

Molecular Weight4,731 g/mol

SequenceAdd product metafield

StorageRefrigerate at 2–8°C

FormLyophilized powder

Research UseFor controlled in-vitro laboratory research only.

Triple GIP, GLP-1 and glucagon receptor agonism Product-specific pathway illustration

RESEARCH AREAS

Retatrutide Potential Use Cases

Product-specific research applications associated with Prime Peptide Retatrutide.

Triple receptor agonist characterization

GLP-1 receptor signaling research

GIP receptor signaling research

Glucagon receptor signaling research

Metabolic pathway research

In-vitro pharmacodynamic assay development

KEY BENEFITS

Retatrutide Research Highlights

Key research-oriented characteristics connected to Prime Peptide Retatrutide.

Supports study of three receptor systems within one research model
Suitable for comparative multi-receptor signaling experiments
Connects directly to reusable receptor-target and citation records
Available with batch-specific documentation

SPECIFICATIONS

Retatrutide Molecular Data

Molecular specifications for Prime Peptide Retatrutide
Molecular Formula	C221H342N46O68
Molecular Weight	4,731 g/mol
Purity	>99% by HPLC
Appearance	White powder
Solubility	Solubility depends on concentration, pH, counterion, and solvent system. Follow the batch COA and validated laboratory protocol.
Storage	Refrigerate at 2–8°C
Research Use	For controlled in-vitro laboratory research only.

3D Structure · Representative Model

BIOLOGICAL & MOLECULAR TARGETS

Retatrutide Research Targets

GLP-1 receptor

GLP-1R

G protein-coupled receptor

The glucagon-like peptide-1 receptor is one of the three G protein-coupled receptors associated with Retatrutide. This target entry supports receptor-activation, downstream signaling and comparative multi-receptor assay interpretation.

View reference ↗

GIP receptor

GIPR

G protein-coupled receptor

The glucose-dependent insulinotropic polypeptide receptor is one of the three G protein-coupled receptors associated with Retatrutide. This target entry supports receptor-activation, downstream signaling and comparative multi-receptor assay interpretation.

View reference ↗

Glucagon receptor

GCGR

G protein-coupled receptor

The glucagon receptor is one of the three G protein-coupled receptors associated with Retatrutide. This target entry supports receptor-activation, downstream signaling and comparative multi-receptor assay interpretation.

View reference ↗

SCIENTIFIC SOURCES

Retatrutide Citations & References

LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes

The Lancet 2022

Phase 1b study describing LY3437943 (Retatrutide) as a triple agonist at the GIP, GLP-1 and glucagon receptors and reporting early pharmacologic and clinical observations.

Read publication →

Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

New England Journal of Medicine 2023

Phase 2 trial identifying Retatrutide (LY3437943) as an agonist of the GIP, GLP-1 and glucagon receptors and evaluating its dose-response, safety and efficacy in adults with obesity.

Read publication →

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes

The Lancet 2023

Phase 2 study evaluating Retatrutide as a GIP, GLP-1 and glucagon receptor agonist in people with type 2 diabetes.

Read publication →

TERMINOLOGY

Retatrutide Glossary

Retatrutide — An investigational peptide also known as LY3437943 that is studied for activity at the GIP, GLP-1 and glucagon receptors.

Retatrutide is an investigational peptide, also identified as LY3437943, designed to activate the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon receptors. It is studied as a triple receptor agonist in metabolic research.

Also known as: LY3437943 Source ↗

Triple receptor agonist — A compound designed to activate three distinct receptor systems.

In Retatrutide research, triple receptor agonist refers to activity at the GIP receptor, GLP-1 receptor and glucagon receptor within one molecular design.

Also known as: Triple agonist, Tri-agonist Source ↗

GLP-1 receptor — The receptor for glucagon-like peptide-1, a signaling target studied in metabolic and endocrine research.

The glucagon-like peptide-1 receptor (GLP-1R) is a G protein-coupled receptor involved in nutrient-responsive signaling. It is one of the three receptor targets investigated in Retatrutide research.

Also known as: GLP-1R, Glucagon-like peptide-1 receptor Source ↗

GIP receptor — The receptor for glucose-dependent insulinotropic polypeptide, studied in nutrient and metabolic signaling.

The glucose-dependent insulinotropic polypeptide receptor (GIPR) is a G protein-coupled receptor involved in nutrient-responsive signaling. It is one of the three receptor targets investigated in Retatrutide research.

Also known as: GIPR, Glucose-dependent insulinotropic polypeptide receptor Source ↗

Glucagon receptor — The receptor for glucagon, studied in glucose, hepatic and energy-metabolism signaling.

The glucagon receptor (GCGR) is a G protein-coupled receptor involved in glucose and energy-metabolism signaling. It is one of the three receptor targets investigated in Retatrutide research.

Also known as: GCGR Source ↗

Pharmacodynamics — The study of what a compound does to a biological system, including receptor activity and downstream responses.

Pharmacodynamics examines the relationship between a compound, its molecular targets and the biological responses that follow. In Retatrutide research, this includes investigation of signaling through the GIP, GLP-1 and glucagon receptors.

COMMON RESEARCH QUESTIONS

Retatrutide FAQ

What is Retatrutide?

Retatrutide, also known as LY3437943, is an investigational peptide designed for activity at the GIP, GLP-1 and glucagon receptors. It is studied as a triple receptor agonist in metabolic research.

Which receptors does Retatrutide target?

Published research describes Retatrutide as an agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor, glucagon-like peptide-1 (GLP-1) receptor and glucagon receptor.

What is Retatrutide studied for in laboratory research?

Retatrutide is studied in receptor-signaling, pharmacodynamic and metabolic-pathway research involving the GIP, GLP-1 and glucagon receptor systems. The product information on this page is presented for controlled in-vitro laboratory research context.

Is this Retatrutide product intended for laboratory research?

Yes. This product is presented for controlled in-vitro laboratory research only. Researchers should review the available batch documentation and follow applicable institutional and jurisdictional requirements.

What sources support the Retatrutide research summary?

The research summary is supported by peer-reviewed studies published in The Lancet and the New England Journal of Medicine. Full citations and reference links are listed in the Sources section of this product page.